$TOVX
Theriva Biologics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000110465921133722 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.486M $1.303M $1.197M
YoY Change 115.61% 8.86% 9.02%
% of Gross Profit
Research & Development $2.779M $1.972M $914.0K
YoY Change 183.57% 115.75% -77.94%
% of Gross Profit
Depreciation & Amortization $13.00K $18.00K $53.00K
YoY Change -59.38% -66.04% -11.67%
% of Gross Profit
Operating Expenses $5.265M $3.275M $2.111M
YoY Change 146.95% 55.14% -59.73%
Operating Profit -$3.275M -$2.111M
YoY Change 55.14%
Interest Expense $2.000K $2.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $2.000K $0.00
YoY Change
Pretax Income -$5.263M -$3.273M -$2.111M
YoY Change 146.86% 55.05% -59.01%
Income Tax
% Of Pretax Income
Net Earnings -$5.263M -$3.273M -$2.103M
YoY Change 149.55% 55.63% -58.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.14
Diluted Earnings Per Share -$398.2K -$0.02 -$0.14
COMMON SHARES
Basic Shares Outstanding 132.0M 132.0M 19.40M
Diluted Shares Outstanding 132.0M 19.40M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.33M $72.14M $6.005M
YoY Change 981.18% 1101.25% -67.8%
Cash & Equivalents $67.33M $72.14M $6.005M
Short-Term Investments
Other Short-Term Assets $1.533M $1.422M $657.0K
YoY Change 23.83% 116.44% -44.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00 $0.00
Total Short-Term Assets $68.86M $73.56M $6.662M
YoY Change 767.89% 1004.13% -66.43%
LONG-TERM ASSETS
Property, Plant & Equipment $101.0K $115.0K $518.0K
YoY Change -41.95% -77.8% -40.87%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $23.00K $23.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.507M $1.564M $541.0K
YoY Change 216.6% 189.09% -39.82%
TOTAL ASSETS
Total Short-Term Assets $68.86M $73.56M $6.662M
Total Long-Term Assets $1.507M $1.564M $541.0K
Total Assets $70.37M $75.12M $7.203M
YoY Change 736.68% 942.91% -65.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $524.0K $1.255M $992.0K
YoY Change -40.86% 26.51% -59.54%
Accrued Expenses $1.928M $1.009M $2.018M
YoY Change 108.43% -50.0% -36.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.554M $3.160M $3.010M
YoY Change 19.82% 4.98% -46.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.403M $1.401M $261.0K
YoY Change 654.3% 436.78% -51.58%
Total Long-Term Liabilities $1.403M $1.401M $261.0K
YoY Change 654.3% 436.78% -51.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.554M $3.160M $3.010M
Total Long-Term Liabilities $1.403M $1.401M $261.0K
Total Liabilities $4.957M $4.561M $521.0K
YoY Change 57.27% 775.43% -84.36%
SHAREHOLDERS EQUITY
Retained Earnings -$271.3M -$266.0M
YoY Change 9.35%
Common Stock $336.7M $339.4M
YoY Change 39.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.41M $73.33M $6.682M
YoY Change
Total Liabilities & Shareholders Equity $70.37M $75.12M $7.203M
YoY Change 736.68% 942.91% -65.27%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$5.263M -$3.273M -$2.103M
YoY Change 149.55% 55.63% -58.93%
Depreciation, Depletion And Amortization $13.00K $18.00K $53.00K
YoY Change -59.38% -66.04% -11.67%
Cash From Operating Activities -$4.810M -$2.156M -$2.050M
YoY Change 53.58% 5.17% -33.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$4.000K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$4.000K
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.810M -2.156M -2.050M
Cash From Investing Activities 0.000 0.000 -4.000K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -4.810M -2.156M -2.054M
YoY Change -2266.67% 4.97% -32.92%
FREE CASH FLOW
Cash From Operating Activities -$4.810M -$2.156M -$2.050M
Capital Expenditures $0.00 $0.00 -$4.000K
Free Cash Flow -$4.810M -$2.156M -$2.046M
YoY Change 53.82% 5.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3973
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
120000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132042538
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19398339
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118448633
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18302585
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
SYNTHETIC BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SYN
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
132042538
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72135000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6227000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1422000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1707000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
73557000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
7934000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1426000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
279000
CY2021Q3 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2020Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2021Q3 us-gaap Assets
Assets
75121000
CY2020Q4 us-gaap Assets
Assets
8410000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1255000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
886000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1009000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
925000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
721000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
868000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
287000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3160000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2966000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1401000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
186000
CY2021Q3 us-gaap Liabilities
Liabilities
4561000
CY2020Q4 us-gaap Liabilities
Liabilities
3152000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
120000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12798000
us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3973
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
2477000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132044866
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132042538
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29252253
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29249925
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
132000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339223000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
240821000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266021000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248094000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
73334000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4767000
CY2021Q3 us-gaap Minority Interest
MinorityInterest
-2774000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-2773000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70560000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75121000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8410000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1197000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3988000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3876000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1972000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
914000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5021000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4152000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3275000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2111000
us-gaap Operating Expenses
OperatingExpenses
9009000
us-gaap Operating Expenses
OperatingExpenses
8028000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3275000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2111000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9009000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8028000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2021Q1 syn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8042000
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-3273000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-2111000
us-gaap Profit Loss
ProfitLoss
-9005000
us-gaap Profit Loss
ProfitLoss
-7984000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-50000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3273000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2103000
us-gaap Net Income Loss
NetIncomeLoss
-9004000
us-gaap Net Income Loss
NetIncomeLoss
-7934000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3273000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2686000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17926000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9438000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132042538
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19398339
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118448633
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18302585
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
101000
CY2021Q1 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
65960000
CY2021Q1 syn Adjustments To Effect Of Preferred Stock Price
AdjustmentsToEffectOfPreferredStockPrice
0
CY2021Q1 syn Conversionofseriesbpreferredstocktocommonstock
Conversionofseriesbpreferredstocktocommonstock
12822000
CY2021Q1 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2536000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76824000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
102000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73731000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
102000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3273000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70560000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1057000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
83000
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
62000
CY2020Q1 syn Stock Issued During Period Value Of Syn Biomics Stock
StockIssuedDuringPeriodValueOfSynBiomicsStock
26000
CY2020Q1 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2964000
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4000000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
86000
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
63000
CY2020Q2 syn Stock Issued During Period Value Of Syn Biomics Stock
StockIssuedDuringPeriodValueOfSynBiomicsStock
10000
CY2020Q2 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2867000
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-16000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6850000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
82000
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
64000
CY2020Q3 syn Stock Issued During Period Value Of Syn Biomics Stock
StockIssuedDuringPeriodValueOfSynBiomicsStock
142000
CY2020Q3 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2103000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8801000
us-gaap Profit Loss
ProfitLoss
-9005000
us-gaap Profit Loss
ProfitLoss
-7984000
us-gaap Share Based Compensation
ShareBasedCompensation
305000
us-gaap Share Based Compensation
ShareBasedCompensation
251000
syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
0
syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
178000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
169000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-285000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-724000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
123000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
103000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
368000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1324000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
85000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-788000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-147000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-182000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-168000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-183000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8080000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9036000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65960000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8042000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74002000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
65908000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9040000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6227000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15045000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72135000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6005000
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
7402000
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1270000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2477000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2177000
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1496000
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1315000
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
24000
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
189000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q3 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1182000
CY2020Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
470000
CY2021Q3 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
157000
CY2020Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
90000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
83000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
639000
CY2021Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
469000
CY2021Q3 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
0
CY2020Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
39000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1422000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1707000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
932000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1263000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
817000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1089000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174000
CY2021Q3 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
756000
CY2020Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
700000
CY2021Q3 syn Accrued Vendor Payments
AccruedVendorPayments
253000
CY2020Q4 syn Accrued Vendor Payments
AccruedVendorPayments
225000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1009000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
925000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
50000
us-gaap Operating Lease Cost
OperatingLeaseCost
151000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
80000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
543000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
724000
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
178000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
144000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
721000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
868000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
380000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
us-gaap Operating Lease Payments
OperatingLeasePayments
240000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
77000
us-gaap Operating Lease Payments
OperatingLeasePayments
231000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1300000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2020 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
900000
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
CY2021Q3 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18000713
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
-11655747
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0.69
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6344966
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
328000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2020 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
900000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2018Q4 syn Percentage Of Issue Of The Public Offering
PercentageOfIssueOfThePublicOffering
1.20
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8996768
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8996768
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
78700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66000000.0
syn Number Of Operating Lease For Facilities
NumberOfOperatingLeaseForFacilities
1
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2021Q3 syn Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2021Q3 syn Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
77000
us-gaap Operating Lease Cost
OperatingLeaseCost
195000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
81000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
247000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
327000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
337000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
347000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
357000
CY2021Q3 syn Lessee Operating Lease Liability To Be Paid Year Six
LesseeOperatingLeaseLiabilityToBePaidYearSix
368000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2064000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
488000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1576000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1401000

Files In Submission

Name View Source Status
0001104659-21-133722-index-headers.html Edgar Link pending
0001104659-21-133722-index.html Edgar Link pending
0001104659-21-133722.txt Edgar Link pending
0001104659-21-133722-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20210930.xsd Edgar Link pending
syn-20210930x10q.htm Edgar Link pending
syn-20210930x10q001.jpg Edgar Link pending
syn-20210930x10q_htm.xml Edgar Link completed
syn-20210930xex31d1.htm Edgar Link pending
syn-20210930xex32d1.htm Edgar Link pending
syn-20210930_cal.xml Edgar Link unprocessable
syn-20210930_def.xml Edgar Link unprocessable
syn-20210930_lab.xml Edgar Link unprocessable
syn-20210930_pre.xml Edgar Link unprocessable